Cancer — Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
Citation(s)
An Open-label, Phase 1b Study of Intravenously Administered Pegylated Liposomal Mitomycin C Lipid-based Prodrug (PROMITIL) in Combination With External Beam Radiotherapy in Patients With Advanced Cancer Requiring Palliative Radiotherapy